Financial Performance - The company's operating revenue for Q1 2023 was RMB 246,355,024.32, representing a decrease of 4.18% compared to the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was RMB 55,861,404.05, down 24.53% year-on-year[5] - The net profit after deducting non-recurring gains and losses was RMB 49,607,213.75, reflecting a decline of 33.36% compared to the previous year[5] - Basic and diluted earnings per share for Q1 2023 were both RMB 0.15, a decrease of 21.05% year-on-year[7] - The weighted average return on equity was 2.03%, down by 0.92 percentage points compared to the previous year[7] - The report indicates that the company is committed to enhancing its market position through strategic investments in R&D and product development[10] - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[16] - The net profit for Q1 2023 was CNY 55,861,404.05, a decrease of 24.5% compared to CNY 74,021,366.53 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 62,341,671.90, down 26.0% from CNY 84,279,091.21 in the same period last year[18] Cash Flow - The net cash flow from operating activities was negative RMB 120,197,574.28, indicating a significant cash outflow[7] - The net cash flow from operating activities was not applicable, primarily due to increased R&D expenditures and higher cash outflows for raw material purchases influenced by "volume-based procurement"[10] - Cash flow from operating activities in Q1 2023 showed a net outflow of CNY 120,197,574.28, compared to a net outflow of CNY 20,120,816.00 in Q1 2022[21] - Cash inflow from investment activities in Q1 2023 was CNY 771,181,481.64, compared to CNY 904,215.33 in Q1 2022[21] - Cash outflow for the purchase of fixed assets and intangible assets in Q1 2023 was CNY 1,025,917.03, significantly lower than CNY 21,232,408.43 in Q1 2022[21] - The net increase in cash and cash equivalents was -$118,849,021.05, a notable decline from -$710,667,029.94 in the previous period[22] - The ending balance of cash and cash equivalents stood at $838,344,639.97, down from $1,025,826,965.44 in the previous period[22] Assets and Liabilities - Total assets at the end of Q1 2023 were RMB 3,391,412,670.08, a slight decrease of 0.54% from the end of the previous year[7] - Current assets totaled CNY 2,745,321,590.09, a slight decrease from CNY 2,779,088,982.86 in the previous year[14] - Non-current assets increased to CNY 646,091,079.99 from CNY 630,677,708.05 year-over-year[14] - Total liabilities decreased to CNY 615,416,974.31 from CNY 690,066,911.19 in the previous year[15] - Shareholders' equity rose to CNY 2,775,995,695.77, up from CNY 2,719,699,779.72 year-over-year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,766, with the top ten shareholders holding significant stakes[11] - The largest shareholder, Shi Chunbao, held 29.88% of the shares, while the second-largest shareholder, Yue Shujun, held 24.84%[11] - The top ten shareholders include various institutional and individual investors, indicating a diverse ownership structure[12] - The company has not reported any significant changes in the relationships or agreements among the top shareholders[12] - The company has not disclosed any significant pledges or freezes on shares held by the top shareholders[12] Research and Development - Research and development expenses totaled RMB 33,270,315.66, accounting for 13.51% of operating revenue, an increase of 0.63 percentage points year-on-year[7] - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 33.36% due to the impact of "volume-based procurement" leading to a decline in terminal selling prices and increased R&D investments[10] - The company is focusing on long-term strategic planning, emphasizing the development of new products, technologies, and processes to drive innovation and product iteration[10] - The company has increased its R&D investment to support technological innovation and product upgrades[10] - Research and development expenses for Q1 2023 were CNY 33,270,315.66, slightly up from CNY 33,114,231.75 in Q1 2022[18] Operating Costs - Total operating costs increased to CNY 183,535,965.29, up 7.8% from CNY 170,342,269.72 in the previous year[16] - Operating costs included CNY 77,916,277.20 in operating expenses, which rose significantly from CNY 50,214,509.64 in Q1 2022[16] - The company recorded a decrease in sales expenses to CNY 64,965,051.80 in Q1 2023 from CNY 79,897,136.99 in Q1 2022, a reduction of 18.7%[18] Foreign Exchange and Accounting - The company recorded a foreign exchange gain of CNY 2,022,556.16 in Q1 2023, compared to a gain of CNY 1,695,561.64 in Q1 2022, indicating an increase of 19.2%[18] - The impact of exchange rate changes on cash and cash equivalents was -$218,020.84, reflecting currency fluctuations during the period[22] - The company did not apply new accounting standards or interpretations for the first quarter of 2023[23]
春立医疗(01858) - 2023 Q1 - 季度业绩